
SWTX Valuation
SpringWorks Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
SWTX Relative Valuation
SWTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SWTX is overvalued; if below, it's undervalued.
Historical Valuation
SpringWorks Therapeutics Inc (SWTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.27 is considered Undervalued compared with the five-year average of -15.93. The fair price of SpringWorks Therapeutics Inc (SWTX) is between 330.26 to 339.80 according to relative valuation methord. Compared to the current price of 46.98 USD , SpringWorks Therapeutics Inc is Undervalued By 85.77%.
Relative Value
Fair Zone
330.26-339.80
Current Price:46.98
85.77%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
8.40
P/B
Median3y
4.63
Median5y
5.57
-4.80
FCF Yield
Median3y
-9.37
Median5y
-6.95
Competitors Valuation Multiple
The average P/S ratio for SWTX's competitors is 254.94, providing a benchmark for relative valuation. SpringWorks Therapeutics Inc Corp (SWTX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 133.68%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch

RXRX
Recursion Pharmaceuticals Inc
6.260
USD
-2.64%

CSAN
Cosan SA
4.250
USD
+0.24%

KLIC
Kulicke and Soffa Industries Inc
34.250
USD
-1.52%

ODD
Oddity Tech Ltd
69.430
USD
-0.70%

AMRX
Amneal Pharmaceuticals Inc
8.000
USD
-0.87%

IREN
IREN Ltd
18.140
USD
-4.48%

MRCY
Mercury Systems Inc
52.460
USD
-0.85%

SGRY
Surgery Partners Inc
21.010
USD
-5.45%

AIN
Albany International Corp
71.810
USD
-0.99%

BANC
Banc of California Inc
14.590
USD
-4.39%
FAQ

Is SpringWorks Therapeutics Inc (SWTX) currently overvalued or undervalued?
SpringWorks Therapeutics Inc (SWTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.27 is considered Undervalued compared with the five-year average of -15.93. The fair price of SpringWorks Therapeutics Inc (SWTX) is between 330.26 to 339.80 according to relative valuation methord. Compared to the current price of 46.98 USD , SpringWorks Therapeutics Inc is Undervalued By 85.77% .

What is SpringWorks Therapeutics Inc (SWTX) fair value?

How does SWTX's valuation metrics compare to the industry average?

What is the current P/B ratio for SpringWorks Therapeutics Inc (SWTX) as of Jul 25 2025?

What is the current FCF Yield for SpringWorks Therapeutics Inc (SWTX) as of Jul 25 2025?

What is the current Forward P/E ratio for SpringWorks Therapeutics Inc (SWTX) as of Jul 25 2025?
